Evidence map›Paper›PMID 40827693›Full record

ArticleBioanalysis2025

Pharmacokinetic study of isavuconazonium in human plasma measured by HPLC-MS/MS and its use in healthy Chinese subjects.

Linlin Qiu, Jie Lin, Yuchen Su, Yifu Kong, Yanli Zhou, Yifang Chen, Yonghua Yu

Abstract read
In one paragraph

Article in Bioanalysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Linlin QiuThe First People's Hospital of Linping District, Hangzhou, Zhejiang Province, China.
Jie LinFuan Pharmaceutical Group Ningbo Team Pharmaceutical Co Ltd., Ningbo, China.
Yuchen SuFuan Pharmaceutical Group Ningbo Team Pharmaceutical Co Ltd., Ningbo, China.
Yifu KongFuan Pharmaceutical Group Ningbo Team Pharmaceutical Co Ltd., Ningbo, China.
Yanli ZhouThe First People's Hospital of Linping District, Hangzhou, Zhejiang Province, China.
Yifang ChenThe First People's Hospital of Linping District, Hangzhou, Zhejiang Province, China.
Yonghua YuFuan Pharmaceutical Group Ningbo Team Pharmaceutical Co Ltd., Ningbo, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo establish a rapid, sensitive HPLC-MS/MS method for quantifying isavuconazonium in human plasma and characterize its pharmacokinetics in healthy Chinese subjects under fasting and postprandial conditions. MATERIALS &

methodsPlasma samples were processed via acetonitrile protein precipitation. Separation was performed on an LC-20ADXR Plus C18 column with gradient elution (0.01% formic acid/acetonitrile). Detection used a Triple Quad 4500 mass spectrometer with MRM; isavuconazole-d4 was the internal standard. The method was validated, then applied to a crossover study in 32 healthy subjects (fasting vs. postprandial).

resultsThe method showed good linearity (4-4000 ng/mL, R

conclusionsThe validated HPLC-MS/MS method is rapid and reliable for therapeutic drug monitoring. Food affects absorption but not total exposure, guiding clinical dosing in Chinese populations.

Indexed as

NitrilesPyridinesTandem Mass SpectrometryTriazolesAdultChinaChromatography, High Pressure LiquidCross-Over StudiesEast Asian PeopleFemaleHealthy VolunteersHumansLiquid Chromatography-Mass SpectrometryMaleYoung AdultNitrilesPyridinesTriazolesHPLC-MS/MShuman plasmaIsavuconazonium sulfatemethod validationpharmacokinetic

Identifiers

PMID40827693
PMCPMC12416188

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.